Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP) has announced the publication of Phase 2a trial results in Nature Medicine, demonstrating that a single 21.5 mg dose of SPL026 achieved statistically significant and clinically meaningful reductions in depressive symptoms versus placebo in patients with moderate-to-severe major depressive disorder. The study met its primary endpoint at two weeks with a mean MADRS difference of -7.35 (p=0.023), and effects were observed as early as one week. The treatment was generally well tolerated with no treatment-related serious adverse events.
These findings are important because they provide robust evidence for the potential of SPL026 as a novel treatment for major depressive disorder, a condition affecting millions worldwide with limited effective options. The durability of response is particularly noteworthy: benefits were sustained for up to three months in the open-label phase, with some participants maintaining response up to six months. This suggests that a single dose could offer long-lasting relief, addressing a key unmet need in depression care.
The publication in Nature Medicine, a high-impact peer-reviewed journal, adds credibility to the results and supports the continued development of Helus Pharma’s proprietary serotonergic agonist program. The company is also developing HLP004 for generalized anxiety disorder, which is in Phase 2 trials. The positive SPL026 data could accelerate interest in these programs and potentially lead to new treatment options for mental health conditions.
For investors, the results reinforce the potential of Helus Pharma’s approach to targeting serotonin pathways to promote neuroplasticity. The company’s lead program, HLP003, is in Phase 3 clinical development for major depressive disorder and has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. The SPL026 data may also provide insights that could benefit the broader pipeline.
The full press release is available at https://ibn.fm/etsES. More information about Helus Pharma can be found at www.helus.com. The company operates in Canada, the United States, the United Kingdom, and Ireland.
